

### Sunday September 4, 2022

- 16:00**      **Opening Ceremony**
- 16:20**      **Patient Testimonial**
- 16:50**      **Musical Interlude**
- 17:00**      **EFMC Awards Ceremony**
- 17:20**      **Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology  
Award Lecture**  
Prof. Herbert WALDMANN  
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
- 18:05**      **GDCh - Klaus Grohe Prize Ceremony**
- 18:15**      **Klaus Grohe Prize  
Award Lecture**
- 19:00**      **Welcome Reception**
- 20:00**      **End of the Day**

## Programme

### Monday September 5, 2022

- 08:30 UCB Ehrlich Award for Excellence in Medicinal Chemistry Award Lecture**  
Prof. Mike WARING  
(UNIVERSITY OF NEWCASTLE, Newcastle upon Tyne, United Kingdom)
- 09:15 Discovery of Lead Compounds and Drug Candidates : Opportunities Unique to the World of Small Molecules**  
Prof. Benoit DEPRez  
(INSTITUT PASTEUR DE LILLE, Lille, France)
- 10:00 Exhibition & Coffee**

#### Session *Session 1 'Chemical Biology'*

##### Beyond PROTACS, Monovalent and Glues Degraders

- 10:30 Session Chair**  
Dr Laura M. LUH  
(BAYER, Berlin, Germany)
- 10:35 Strategies to Discover Molecular Glue Degraders at Scale**  
Dr Cristina MAYOR-RUIZ  
(IRB BARCELONA, Barcelona, Spain)
- 11:15 Title to be announced**  
Dr Nicolas THOMÄ  
(FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
- 11:35 Antibody-Protac Conjugates: an Approach for Targeted Selective BRD4 Degradation in HER2+ Phenotypes**  
Dr María MANEIRO  
(UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, Santiago de Compostela, Spain)
- 11:55 Discovery And Profiling of AZ-6421: an Oral ER $\alpha$ -Protac with an in vitro-in vivo Disconnect**  
Dr Thomas HAYHOW  
(ASTRAZENECA, Cambridge, United Kingdom)

#### Session *Session 2 'Drug Discovery'*

##### Renaissance of Natural-Product Inspired Drug Discovery in the 21st Century

- 10:30 Session Chair**  
Dr Boris VAUZEILLES  
(INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES, Gif-sur-Yvette, France)
- 10:35 Big Data Analyses for the Discovery of Lead Structures from Nature**  
Prof. Judith ROLLINGER  
(UNIVERSITY OF VIENNA, Vienna, Austria)
- 11:15 Design of Naturally Inspired Anti-Cancer Compounds that Modulate Cholesterol Homeostasis**  
Dr Fanny ROUSSI  
(ICSN - CNRS, Gif sur Yvette, France)
- 11:35 Title to be announced**  
Speaker to be confirmed
- 11:55 Tuning the Reactivity of the Natural Product Andrographolide: Towards Targeted Covalent Inhibitors for the Treatment of Inflammation**  
Prof. Christina CHAI  
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore)

#### Session *Session 3 'Technologies'*

##### Methods for Late-Stage Functionalization

- 10:30 Session Chair**

## Programme

Prof. Tobias RITTER  
(MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mulheim, Germany)

**10:35 Title to be announced**

Prof. Matthew GAUNT  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

**11:15 Late Stage Tritiation of Drug- and PET-Tracer-Candidates**

Dr Dieter MURI  
(ROCHE · PHARMA RESEARCH AND EARLY DEVELOPMENT (PRED), Basel, Switzerland)

**11:35 Title to be announced**

Prof. Tanja GAICH  
(UNIVERSITY OF KONSTANZ, Konstanz, Germany)

**11:55 Chemical Modification of Wild-type Proteins**

Dr Bauke ALBADA  
(WUR, Wageningen, The Netherlands)

**12:15 Exhibition & Lunch  
Company workshop(s)**

**Session Flash Poster Session 1**

**Session Flash Poster Session 2**

**Session Flash Poster Session 3**

**Session Session 4 'Chemical Biology'**

**Targeting Epigenetic Modifications in Cancer Therapy / ICBS Session**

**13:45 Session Chair**

Prof. Zaneta NIKOLOVSKA-COLESKA  
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

**13:50 Disrupting hDot1L and MLL fusion protein interactions as a novel therapeutic strategy**

Prof. Zaneta NIKOLOVSKA-COLESKA  
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

**14:30 New Opportunities for Studying the Function of the Nucleosome Remodeling Factor NURF Through Chemical Inhibition and Degradation**

Prof. William POMERANTZ  
(UNIVERSITY OF MINNESOTA, Minneapolis, United States)

**14:50 Antidotes for Diseases: Chemistry and Biology Match Together to Tackle Epigenetics**

Dr Paola B. ARIMONDO  
(INSTITUT PASTEUR - CNRS, Paris, France)

**15:10 EFMC-YMCS Prize 2021  
A Mating Mechanism to Generate Diversity for the Darwinian Selection of DNA-encoded Synthetic Molecules**

Mr Lluç FARRERA SOLER  
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

**Session Session 5 'Drug Discovery'**

**Drugging the Undruggable : Targeting Transcription Factors / ACSMEDI Session**

**13:45 Session Chair**

Dr Anthony ROMERO  
(ORIC PHARMACEUTICALS, South San Francisco, United States)

**13:50 Attenuating Oncogenic Transcription with Small Molecules**

Prof. Angela KOEHLER  
(MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH, Cambridge, United States)

**14:10 Transcription Factors as Drug-Discovery Targets**

## Programme

Prof. Fraydoon RASTINEJAD  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

**14:50 Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/Cyclin T1 for MYC-Dependent Cancers**

Dr David FREEMAN  
(KRONOS BIO, INC. , Massachussetts, United States)

**15:10 Inhibiting the MYC Oncogene through Cell Active Max-E47 (ME-47)**

Dr Amy BITTNER MCCracken  
(MERCK &CO, New Jersey, United States)

### Session *Session 6 'Technologies'*

#### Hit Discovery with DNA-Encoded Libraries

**13:45 Session Chair**

Dr Andreas BRUNSCHWEIGER  
(TU DORTMUND, Dortmund, Germany)

**13:50 A DNA Barcode with Enhanced Chemical Stability for DNA-encoded Library Design**

Dr Andreas BRUNSCHWEIGER  
(TU DORTMUND, Dortmund, Germany)

**13:50 New Aspects in DNA-encoded Chemical Library Construction and Screening**

Dr Jörg SCHEUERMANN  
(ETH ZURICH, Zürich, Switzerland)

**14:50 Exploiting DNA-encoded Library Technology for the Discovery of Novel Antibody Recruiting Molecules Against LOX-1**

Ms Katherine MACFARLANE  
(UNIVERSITY OF STRATHCLYDE, London, United Kingdom)

**15:10 Photoactivated Covalent Capture of DNA-encoded Fragments to Identify Ligands for Challenging Targets**

Prof. Roderick HUBBARD  
(VERNALIS, Cambridge, United Kingdom)

**15:30 Exhibition & Coffee**

### Session *Session 7*

#### First Time Disclosures - Part 1

**16:00 First-time Disclosure of M1069, a Highly Selective Dual Inhibitor of Adenosine A<sub>2a</sub>/A<sub>2b</sub> Receptors With Improved Therapeutic Activity Compared to A<sub>2a</sub> Receptor Selective Antagonists**

Dr Kai SCHIEMANN  
(MERCK HEALTHCARE KGAA, Darmstadt, Germany)

**16:30 Discovery of BI 456906, a Novel Long-acting GCG/GLP-1 Receptor Dual Agonist for the Treatment of Patients With Obesity**

Dr Peter HAEBEL  
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach Riss, Germany)

**17:00 Discovery of AZD5462, an Oral Agonist of the Relaxin Family Peptide Receptor 1 (RXFP1) for the Treatment of Cardiorenal Disease**

Dr Kenneth GRANBERG  
(ASTRAZENECA, Mölndal, Sweden)

**18:00 Poster Session 1 & Networking**

**19:30 End of the Day**

## Programme

### Tuesday September 6, 2022

**08:30 Prous Institute - Overton and Meyer Award for New Technologies in Drug Discovery Award Lecture**  
Prof. Alessio CIULLI  
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

**10:00 Exhibition & Coffee**

#### Session *Session 8 'Chemical Biology'*

##### Addressing Cooperative Ligand Binding in Drug Discovery / EUCHEMS Session

**10:30 Session Chair**

Prof. Luc BRUNSVELD  
(EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands)

**10:35 Fragment-Based Approaches to Stabilize Protein-Protein Interactions**

Prof. Michelle ARKIN  
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

**11:15 Title to be announced**

Speaker to be confirmed

**11:35 Identification and Structure-activity Relationship Profiling of Positive Allosteric Modulators Targeting Muscarinic Acetylcholine Receptors**

Dr Manuela JORG  
(MONASH UNIVERSITY, Parkville, Australia)

**11:55 Molecular Glues for the 14-3-3 Interactome**

Dr Richard DOVESTON  
(UNIVERSITY OF LEICESTER, Leicester, United Kingdom)

#### Session *Session 9 'Drug Discovery'*

##### Time to Act Against Antimicrobial Resistance

**10:30 Session Chair**

Prof. Maria-Jesus PÉREZ-PÉREZ  
(INSTITUTO DE QUÍMICA MÉDICA, Madrid, Spain)

**10:35 The Global Antibiotic R&D Partnership: Helping to Advance the Discovery & Development of New Treatments for Bacterial Infections**

Prof. Laura PIDDOCK  
(GLOBAL ANTIBIOTIC R&D PARTNERSHIP, Geneva, Switzerland)

**11:15 Novel Tetrazole Inhibitor of Mycobacterium Tuberculosis Tryptophan Synthase**

Dr Lourdes ENCINAS  
(GLAXOSMITHKLINE, Madrid, Spain)

**11:35 Discovery of ANT3310, a Novel Broad-Spectrum Serine ? Lactamase Inhibitor of the Diazabicyclooctane Class, which strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter Baumannii**

Dr David DAVIES  
(ANTABIO SAS, Labège, France)

**11:55 Discovery of Pseudomonas Aeruginosa Elastase LasB Inhibitors by in Situ Click Chemistry**

Dr Virgyl CAMBERLEIN  
(HIPS - HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND, Saarbrücken, Germany)

#### Session *Sessions 10 'Technologies'*

##### New Screening Technologies : Affinity Selection - Mass Spectrometry

**10:30 Session Chair**

## Programme

Dr Didier ROCHE  
(EDELIRIS, Lyon, France)

**10:35 Title to be announced**

Prof. Wenqing SHUI  
(SHANGHAITECH UNIVERSITY, Shanghai, China)

**11:15 EDELIRIS Keymical Space™ and GPCR : Identification of Allosteric Binders by AS-MS**

Dr Renaud PRUDENT  
(EDELIRIS, Lyon, France)

**11:35 High Throughput Affinity Screening for Rapid Hit Discovery and Prosecuting Intractable Targets**

Mr Jarrod WALSH  
(ASTRAZENECA, Macclesfield, United Kingdom)

**11:55 Title to be announced**

Speaker to be confirmed

**12:15 Exhibition & Lunch  
Company workshop(s)**

**Session Flash Poster Session 4**

**Session Flash Poster Session 5**

**Session Flash Poster Session 6**

**Session Session 11 'Chemical Biology'**

**Targeting Self-Associating Proteins & Biomolecular Condensates in Drug Discovery**

**13:45 Session Chair**

Prof. Raphaël FREDERICK  
(UCLouvain, Brussels-Woluwe, Belgium)

**13:50 Targeting Protein-Protein Interactions of Receptor Complexes**

Prof. Kristian STROMGAARD  
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

**14:10 Leveraging Biomolecular Condensates for Drug Discovery**

Dr Marta FRIGOLE-VIVAS  
(DEWPOINT THERAPEUTICS GMBH, Dresden, Germany)

**14:50 Title to be announced**

Speaker to be confirmed

**15:10 Title to be announced**

Speaker to be confirmed

**Session Session 12 'Drug Discovery'**

**Covalent Drugs**

**13:45 Session Chair**

Dr. Samir JEGHAM  
(SANOFI R&D, MONTPELLIER, France)

**13:50 Inhibiting KRAS: Strategies, Structures, and Lessons Learned in the Invention of Sotorasib**

Dr Brian LANMAN  
(AMGEN, Thousand Oaks, CA, United States)

**14:30 Covalent Fragment Approaches in Drug Discovery**

Prof. Gyorgy KESERU  
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

**14:50 Discovery of Covalent Protein Kinase Inhibitors**

## Programme

Prof. Matthias GEHRINGER  
(UNIVERSITY OF TUEBINGEN, Tuebingen, Germany)

**15:10 Discovery of Novel Covalent, EGFR WT Sparing, HER2 Selective Inhibitors for the Treatment of Her2 Exon 20 Insertion Driven Tumours**

Dr Birgit WILDING  
(BOEHRINGER INGELHEIM, Vienna, Austria)

### Session *Session 13 'Technologies'*

#### Next Generation Medicinal Chemistry - an EFMC<sup>2</sup> Session

**13:45 Session Chair**

Dr Clara CHRIST  
(BAYER PHARMA, Berlin, Germany)

**13:50 Introduction to EFMC<sup>2</sup>**

Dr Richard LEWIS (NOVARTIS PHARMACEUTICALS, Basel, Switzerland)  
Dr Franz VON NUSSBAUM (NUVISAN ICB GMBH, Berlin, Germany)

**14:00 Automating Lead Optimisation with BRADSHAW**

Dr Darren GREEN  
(GSK, Stevenage, United Kingdom)

**14:30 A Perspective on AI and Automation for the Medicinal Chemistry Lab**

Prof. Connor COLEY  
(MIT, Cambridge)

**14:50 The Power and Pitfalls of Machine Learning in Early Stage Drug Discovery**

Prof. Charlotte DEANE  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

**15:10 Using AI to Derive Valuable Insights from Drug Discovery Data**

Dr Matthew SEGALL  
(OPTIBRIUM, Cambridge, United Kingdom)

**15:30 Exhibition & Coffee**

### Session *Session 14*

#### First Time Disclosures -Part 2

**16:00 MPGES1 Inhibitors: First Time Disclosure of Clinical Candidate BI01029539 / GS-248**

Dr Roland PFAU  
(BOEHRINGER INGELHEIM PHARMA GMBH&CO. KG, Ingelheim am Rhein, Germany)

**16:30 First Disclosure of Cannabinoid Receptor Type 2 Agonist Rg7774 – An Innovative Oral Treatment for Diabetic Retinopathy**

Dr Uwe GREETHER  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

**17:00 Discovery and Optimisation of Potent, Slow-dissociating Inhaled PI4KB Inhibitors**

Dr Sophie BERTRAND  
(GSK, Stevenage, United Kingdom)

**18:00 Poster Session 2 & Networking**

**19:30 End of Poster Session**

## Programme

### Wednesday September 7, 2022

- 08:30**     **Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire**  
Prof. Sarah E. REISMAN  
(CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States)
- 09:15**     **EFMC Prizes for Young Medicinal Chemist or Chemical Biologist in Academia and in Industry Ceremony & Lectures**
- 10:00**     **Exhibition & Coffee**

#### Session *Session 15 'Chemical Biology'*

##### In vivo Chemistry to Study Biological Mechanisms and to Develop Innovative Tools for Therapy and Diagnosis

- 10:30**     **Session Chair**  
Dr Frédéric TARAN  
(CEA/SACLAY, Gif-sur-Yvette, France)
- 10:35**     **Title to be announced**  
Dr Marc ROBILLARD  
(TAGWORKS PHARMACEUTICALS, Eindhoven, The Netherlands)
- 11:15**     **Next-level Chemical Tools for Ultrafast Bioorthogonal Bond-Cleavage Reactions**  
Dr Hannes MIKULA  
(TU VIENNA, Vienna, Austria)
- 11:35**     **Enzymatic Photocaging of Nucleic Acids: A Strategy for Controlling Methyltransferase Target Sites by Light**  
Prof. Andrea RENTMEISTER  
(UNIVERSITY OF MÜNSTER, Münster, Germany)
- 11:55**     **Fast Detection and Imaging of Hydrogen Peroxide with New Borinic Probes**  
Dr Boris VAUZEILLES  
(INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES, Gif-sur-Yvette, France)

#### Session *Session 16 'Drug Discovery'*

##### Rising Horizons of Small Molecule Immunotherapies and Beyond

- 10:30**     **Session Chair**  
Prof. Antonio MACCHIARULO  
(UNIVERSITY OF PERUGIA, Perugia, Italy)
- 10:35**     **Tipping the Balance: MALT1 Inhibitors with Paradoxical Effects on the Immune System**  
Dr Jean QUANCARD  
(NOVARTIS, Basel, Switzerland)
- 11:15**     **The discovery of the Clinical Candidate AZD0284, a Novel Orally Bioavailable Inverse Agonist of ROR $\gamma$  for the Treatment of Psoriasis**  
Dr Frank NARJES  
(ASTRAZENECA, Mölndal, Sweden)
- 11:35**     **Macrolide Inspired Macrocycles as Effective Disruptors of the IL-17A/IL-17RA Interaction**  
Dr Sanja KOSTRUN  
(FIDELTA LTD, Zagreb, Croatia)
- 11:55**     **NR2F6 Antagonists: in Vitro Pharmacology and Preclinical Data of a Potential Next Generation Immuno-oncology Therapy**  
Dr Francesco GRECO  
(TES PHARMA SRL, Perugia, Italy)



## Programme

### Session *Session 17 'Technologies'*

#### Innovative Synthetic Technologies for Drug Discovery

- 10:30 Session Chair**  
Dr Cara BROCKLEHURST  
(NOVARTIS, Basel, Switzerland)
- 10:35 Molecular Vending Machines for the On-Demand Synthesis of Drug-Like Molecules**  
Prof. Jeffrey BODE  
(ETH ZÜRICH, Zürich, Switzerland)
- 11:15 Photocatalysis in Drug Discovery**  
Dr Lisa CANDISH  
(BAYER, Wuppertal, Germany)
- 11:35 Visible-light Photocatalysis: a Powerful Tool in the Pursuit of New Pharmaceuticals**  
Dr Giulia BERGONZINI  
(ASTRAZENECA, Mölndal, Sweden)
- 11:55 Iridium-catalyzed C-H Activation Methods for Late-stage Functionalization of Pharmaceuticals**  
Dr Erik WEIS  
(ASTRAZENECA, Mölndal, Sweden)
- 12:15 Exhibition & Lunch  
Company workshop(s)**

### Session *Session 18*

#### Highlights in Medicinal Chemistry Part 1

- 13:15 Session Chair**  
Dr Jan Willem THURING  
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)
- 13:20 Title to be announced**  
Prof. Guy VAN DEN MOOTER  
(KULEUVEN, Leuven, Belgium)
- 14:00 Dual Inhibition of P53-MDM2/4 Interactions With Spiropyrazoline Oxindoles**  
Ms Elizabeth A. LOPES  
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisboa, Portugal)
- 14:20 Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106**  
Dr Timo HEINRICH  
(MERCK, DARMSTADT, Germany)
- 14:40 A New Dual Mode of Action to Treat Pain - From Scratch to Pre-Clinical Candidate**  
Dr Anita WEGERT  
(SYMERES, Nijmegen, The Netherlands)

### Session *Session 19 'Drug Discovery'*

#### Targeting RNA by Small Molecules

- 13:15 Session Chair**  
Dr Hasane RATNI  
(F. HOFFMANN-LA ROCHE LTD, Switzerland)
- 13:20 Enabling Technologies for Revealing Druggable Paths in RNA Biology**  
Dr Amanda GARNER  
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)
- 13:40 Targeting RNA with Small Molecules, A New Therapeutic Strategy**  
Dr Yann FORICHER  
(SANOFI, Vitry-sur-Seine, France)
- 14:20 Fundamental Basis for SMN2 Specific Splicing Correction by Small Molecules and Bulge Repair Mechanism**

## Programme

Dr Sébastien CAMPAGNE  
(INSERM BORDEAUX, BORDEAUX, France)

**14:40 Bis-3-chloropiperidines Targeting TAR RNA as a Novel Strategy to Impair the HIV-1 Nucleocapsid Protein**

Dr Alice SOSIC  
(UNIVERSITY OF PADOVA, Padova, Italy)

### Session *Session 20 'Technologies'*

#### AI in Drug Discovery /CPA Session

**13:15 Session Chair**

Prof. Mingyue ZHENG  
(SHANGHAI INSTITUTE OF MATERIA MEDICA, Shanghai, China)

**13:20 De Novo Drug Design Using 3D Deep Generative Models**

Prof. Jianfeng PEI  
(PEKING UNIVERSITY, Beijing, China)

**14:00 Title to be announced**

Prof. Feng ZHU  
(ZHEJIANG UNIVERSITY, Hangzhou, China)

**14:20 Opportunity and Challenge of Artificial Intelligence (AI) in Drug Delivery**

Prof. Defang OUYANG  
(MACAU UNIVERSITY, Macau, China)

**14:40 In Silico Prediction of Brain Penetration - High Accuracy Achieved**

Dr Herve GENESTE  
(ABBVIE, Ludwigshafen, Germany)

**15:00 End of the Day**

**15:45 Excursions**

**20:00 Banquet**

### Thursday September 8, 2022

#### Session *Session 21 'Chemical Biology'*

##### Mining the Phosphosignaling Networks

**08:30 Session Chair**

Dr Nadia AHMAD  
(CHARLES RIVER LABORATORIES, Harlow, United Kingdom)

**08:35 The Phosphatase Family: a Widely Neglected Target Space for Small-Molecule Drug Discovery**

Dr Gerhard MÜLLER  
(ANAVO THERAPEUTICS, Heidelberg, Germany)

**09:15 Discovery of Novel Kinase Inhibitors Through in Silico Fragment-Based Ligand Screening**

Prof. Pascal BONNET  
(UNIVERSITY OF ORLÉANS, Orléans, France)

**09:35 Title to be announced**

Speaker to be confirmed

**09:55 Mining the Leishmania Kinome**

Dr Exequiel PORTA  
(DURHAM UNIVERSITY, Durham, United Kingdom)

#### Session *Session 22 'Drug Discovery'*

##### New Treatments for Current and Future Pandemics

**08:30 Session Chair**

Prof. Ana MARTINEZ  
(CSIC, Madrid, Spain)

**08:35 Searching for Drugs against Pandemic Viruses. A Case Study**

Dr Carmen GIL  
(CENTRO DE INVESTIGACIONES BIOLÓGICAS (CSIC), Madrid, Spain)

**09:15 Current Challenges in Antiviral Therapies Against Coronaviruses and Other Emerging RNA Viruses**

Dr Karine ALVAREZ  
(AIX-MARSEILLE UNIVERSITY, Marseille, France)

**09:35 Embrace Complexity: in Silico Polypharmacological Profiling to Repurpose Medicines and Design New Drugs**

Dr Andrea BECCARI  
(DOMPÉ PHARMA, L'Aquila, Italy)

**09:55 Human Dihydroorotate Dehydrogenase Inhibitor MEDS443: a Magic Bullet Against Coronaviruses**

Dr Stefano SAINAS  
(UNIVERSITY OF TORINO, Torino, Italy)

#### Session *Session 23*

##### Highlights in Medicinal Chemistry Part 2

**08:30 Session Chair**

Prof. Roberto DI SANTO (SAPIENZA UNIVERSITY OF ROME, Rome, Italy)  
(SANOFI-AVENTIS DEUTSCHLAND GMBH)

**08:35 Title to be announced**

Prof. Michael E. JUNG  
(UCLA CHEMISTRY & BIOCHEMISTRY, Los Angeles, United States)

**09:15 Discovery of Clinical Candidate CHF-6366: a Super-soft Heterobifunctional Muscarinic Antagonist and ?2-adrenoceptor Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases**

Ms Laura CARZANIGA  
(CHIESI FARMACEUTICI SPA, PARMA, Italy)

**09:35 Discovery of JNJ-1245, a Novel and Potent Fluoroallylamide Mcl-1 Inhibitor for the Treatment of Hematologic Malignancies**

## Programme

Dr Soufyan JERHAOUI  
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)

**09:55 Structure-Guided Design of Foldamer-Based Inhibitors of Protein-Protein Interactions**

Dr Gilles GUICHARD  
(CBMN & IECB, UNIVERSITY OF BORDEAUX, CNRS, BORDEAUX INP, Pessac, France)

**10:15 Exhibition & Coffee**

### Session *Session 24 'Chemical Biology'*

#### Chemical Probes for Target Identification & Validation / EUFEPS Session

**10:45 Session Chair**

Dr Joanna REDMOND  
(FRANCIS CRICK INSTITUTE, London, United Kingdom)

**10:50 Chemical Probes and How to Find Them**

Dr Alex PAUTSCH  
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany)

**11:30 De Novo Cyclic Peptides as Chemical Tools to Explore Epigenetic Regulation**

(SANOFI-AVENTIS DEUTSCHLAND GMBH)  
Dr Louise WALPORT (THE FRANCIS CRICK INSTITUTE, London, United Kingdom)

**11:50 Chemical Probes for Targets in Lipid Signalling**

Prof. Eugen PROSCHAK  
(GOETHE UNIVERSITY OF FRANKFURT, Frankfurt/Main, Germany)

**12:10 First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation**

Prof. Rebecca DEPRez-POULAIN  
(UNIVERSITY OF LILLE / INSTITUT PASTEUR OF LILLE, Lille, France)

### Session *Session 25 'Drug Discovery'*

#### Drug Discovery in Targeting Neurodegenerative Disorders / ACSMEDI

**10:45 Session Chair**

Prof. Rong HUANG  
(PURDUE UNIVERSITY, West Lafayette, United States)

**10:50 Exploring Alternative Targets and Development of Precision Medicine Tools for CNS Diseases**

Prof. Daniel Martin WATTERSON  
(NORTHWESTERN UNIVERSITY, Chicago, United States)

**11:30 Discovery of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Autism, Down Syndrome, and Brain Disorders with Defective NKCC1/KCC2 Ratio**

Dr Marco BORGOGNO  
(IAMA THERAPEUTICS SRL, Genoa, Italy)

**11:50 eIF2B Activators Beyond ISRIB: New Integrated Stress Response Inhibitors**

Dr Michael J. DART  
(ABBVIE, North Chicago, United States)

**12:10 Modulation of TDP-43-pathway by Brain Penetrant Protein Kinase Inhibitors, a New Hope for ALS and Related Disorders**

Prof. Ana MARTINEZ  
(CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain)

### Session *Session 26 'Technologies'*

#### Radiochemistry / AFMC Session

**10:45 Session Chair**

Prof. Sun CHOI  
(EWA WOMANS UNIVERSITY, Seoul, Korea, South)

**10:50 Radiotheragnostics from Bench-to-Bedside**

## Programme

- Prof. Roger SCHIBLI  
(ETH ZÜRICH, Zürich, Switzerland)
- 11:30 Title to be announced**  
Dr Mikako OGAWA  
(HOKKAIDO UNIVERSITY, Sapporo, Japan)
- 11:50 Medicinal Chemistry in the Development of Molecular Imaging Probes Targeting Prostate-Specific Membrane Antigen**  
Prof. Youngjoo BYUN  
(KOREA UNIVERSITY, Sejong, Korea, South)
- 12:10 Development of First PET Tracers for the Imaging of CD73 Expression in Triple-negative Breast Cancer**  
Dr Anna JUNKER  
(EUROPEAN INSTITUTE FOR MOLECULAR IMAGING, Muenster, Germany)
- 12:30 Closing Lecture**
- 12:30 Title to be announced**  
Prof. Outi VAARALA  
(ORION CORPORATION, Espoo, Finland)
- 13:15 Closing Remarks, Poster Prizes & Welcome to EFMC-ISMIC 2024**